Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

BTCURE

Financiado

BeTheCuRE

BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal models have to develop the line with the different subsets of the human diseases in order to be... ver más

31/03/2017

UCB

39M€

Presupuesto del proyecto: 39M€

Líder del proyecto

UCB BIOPHARMA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 31 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2017-03-31

0% 100%

31 Participantes

UCB

Lider

CSIC

N.D. | Participante

Leiden University Medical Ce...

N.D. | Participante

MEDIZINISCHE UNIVERSITAET WI...

N.D. | Participante

Proyectos interesantes

STRATA-FIT Stratification of Rheumatoid Arthritis: CompuTational models... 6M€ Cerrado

RTI2018-094120-B-I00 NUEVOS ENFOQUES BASADOS EN PEPTIDOS SINTETICOS PARA EL DIAGN... 121K€ Cerrado

DDRAsTic Targeting DNA Damage Response and Metabolism for Precision M... 223K€ Cerrado

ADJUPROBE LEAD ADJUVANT PROBE AS A DUAL TECHNOLOGICAL TOOL TO ADVANCE... 150K€ Cerrado

PCIN-2017-093 ANTICUERPOS ANTI-FARMACOS Y DETECCION MOLECULAR DE FARMACOS... 121K€ Cerrado

BIOVACSAFE Biomarkers For Enhanced Vaccine Safety 31M€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 71 meses Fecha Inicio: 2011-04-01
Fecha Fin: 2017-03-31

Líder del proyecto

UCB BIOPHARMA

TRL 4-5

Presupuesto del proyecto 39M€

Descripción del proyecto BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal models have to develop the line with the different subsets of the human diseases in order to be optimally used for drug discovery and drug evaluation. Our aim is to develop an understanding of the early process in human arthritis subsets and the animal models that will enable us and EFPIA partners to develop precise and eventually curative treatments to be used before a non-reversible destruction and function loss have occurred. The composition of the consortium include complementarities. Partners are involved to have large cohorts and biobank, to be excellent in understanding and modulating adaptive immunity, and to be able to take both these assets into clinical development of new therapeutics. The aim is to provide the basis for such development together with the EFPIA partners. All partners have a specific role in the development of specific technologies, mouse models, biobanks, systems for studying the adaptive immunity and drug development. Taken together the access for us and the EFPIA partners to this infrastructure and innovative projects will permit the development of new and innovative and ultimately curative therapies for early arthritis.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores